ADSL and respiratory tract infectious disorder: Since no unwanted harmful action at the lung level was pointed out when all the selected AMPs were administered at 0.1 mg/kg, their in vivo efficacy in treating P. aeruginosa-induced respiratory infection was then examined using a mouse model of acute lung infection.